IOBT Overview

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Wall Street analysts forecast IOBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IOBT is1.68 USD with a low forecast of 0.36 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

IO Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

IO Biotech Inc. EPS for the last quarter amounts to -0.13 USD, decreased -63.89 % YoY.

IO Biotech Inc (IOBT) has 80 emplpoyees as of January 30 2026.

Today IOBT has the market capitalization of 23.00M USD.